about
Vitrification of human embryos subjected to blastomere biopsy for pre-implantation genetic screening produces higher survival and pregnancy rates than slow freezing.Embryo selection criteria based on morphology VERSUS the expression of a biochemical marker (sHLA-G) and a graduated embryo score: prediction of pregnancy outcome.Genetic analysis of human embryos by metaphase comparative genomic hybridization (mCGH) improves efficiency of IVF by increasing embryo implantation rate and reducing multiple pregnancies and spontaneous miscarriages.Gonadotropin-releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure.Induction of labor following intrauterine death with intra-amniotic hyperosmolar urea and prostaglandin F2alpha: evaluation of placental endocrine function and changes in coagulation parameters.High survival rate of metaphase II human oocytes after first polar body biopsy and vitrification: determining the effect of previtrification conditions.Selective vitrification of euploid oocytes markedly improves survival, fertilization and pregnancy-generating potential.Correction of postpartum uterine inversion by the application of intravaginal hydrostatic pressure.Performance of the amniotic fluid foam stability--50 percent test. A bedside precedure for the prenatal detection of hyaline membrane disease.In vitro fertilization and embryo transfer: two-year experience.In vitro fertilization (IVF) of mouse ova in HEPES-buffered culture media.Rational basis for foam-stability assays of amniotic fluid surfactant.Effect of vaginal sildenafil on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development.The effect of the biochemical marker soluble human leukocyte antigen G on pregnancy outcome in assisted reproductive technology--a multicenter study.Mock embryo transfer in early luteal phase, the cycle before in vitro fertilization and embryo transfer: a descriptive study.Sclerotherapy with 5% tetracycline is a simple alternative to potentially complex surgical treatment of ovarian endometriomas before in vitro fertilization.The use of combined heparin/aspirin and immunoglobulin G therapy in the treatment of in vitro fertilization patients with antithyroid antibodies.A rational basis for the use of combined heparin/aspirin and IVIG immunotherapy in the treatment of recurrent IVF failure associated with antiphospholipid antibodies.A linear karyotypic association between PB-I, PB-II and blastomere using sequentially performed comparative genome hybridization with no association established between karyotype, morphologic, biochemical (sHLA-G expression) characteristics, blastocComparison of aneuploidy frequencies between in vitro matured and unstimulated cycles oocytes by metaphase comparative genomic hybridization (mCGH).Reproductive oocyte/embryo genetic analysis: comparison between fluorescence in-situ hybridization and comparative genomic hybridization.'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization.High fecundity rates in donor oocyte recipients and in-vitro fertilization surrogates using parenteral oestradiol valerate.Management of suboptimal sonographic endometrial patterns in patients undergoing in-vitro fertilization and embryo transfer.Oocyte karyotyping by comparative genomic hybridization [correction of hybrydization] provides a highly reliable method for selecting "competent" embryos, markedly improving in vitro fertilization outcome: a multiphase study.Influence of early ICSI-derived embryo sHLA-G expression on pregnancy and implantation rates: a prospective study.Expression of sHLA-G in supernatants of individually cultured 46-h embryos: a potentially valuable indicator of 'embryo competency' and IVF outcome.Soluble human leukocyte antigen G expression in phase I culture media at 46 hours after fertilization predicts pregnancy and implantation from day 3 embryo transfer.Comparing the British and American approaches to regulating ART programmes.sHLA-G expression: is it really worth measuring?Abruptio placentae with coagulopathy: a rational basis for managementAccountability, representation, and advertisingAssessing fetal lung maturation by the foam stability index testEvaluation of a modified foam stability (FS-50) test. An assay performed on amniotic fluid to predict fetal pulmonary maturityAn improved system for catheter loading during embryo transferEvaluation of the small third-trimester fetus using the foam stability index testAssessment of the late proliferative phase endometrium by ultrasonography in patients undergoing in-vitro fertilization and embryo transfer (IVF/ET)Diagnostic reliability of the lecithin/sphingomyelin ratio assay and the quantitative foam stability index test: results of a comparative studyThe major determinants of perinatal mortality in a large metropolitan hospital. Results of a retrospective studyIn vitro sperm capacitation and transcervical intrauterine insemination for the treatment of refractory infertility: phase I
P50
Q33563491-2fd2e8e1-454b-a680-4db6-93df51816b7dQ34038953-28396ee3-423d-4521-509d-49f1e9042f60Q34602942-10501e30-4a2b-96aa-6f80-207326630e3bQ34636478-cefdf72b-41b3-49c1-8309-3f8df54227ffQ40867941-2f1a44a8-44fb-9444-8c42-9d4579e8a01eQ41610974-bbbe5c10-4cab-dadc-be78-10d2e58b7e58Q41610989-d5cc955e-4ab9-2ced-1236-12f4a57f18aaQ41661772-86620c91-4b2a-30c9-8097-f614e07cd53aQ41719061-7b6cbc77-4a24-db3e-6842-78a6ea4e880aQ43816202-cbddaf12-4269-c98c-5e71-1b6f85320a1dQ43987445-451ddd41-4379-f31f-9710-a101ddcc766dQ43990699-7d5dd66c-4041-5af2-deb4-f01758824c64Q44203359-63c5f3dc-486f-073f-d97d-d4d1087fe1ecQ44428080-66345350-4463-663e-292f-ff66ab7359b8Q44932794-c2917bd5-4e18-3f5e-d5eb-f0bcee6a1aabQ45012216-00e11b20-4b1a-6270-a835-e33814f67d3cQ46252463-3a16655c-4c63-abc4-5816-0abfff0b7393Q47916416-a643e2cd-493d-5001-44dc-f6c1c42d560dQ48642137-0f1d15b4-4cad-5f86-ff9c-63d103948fc6Q48658330-9821fbda-4f70-5528-89cf-819f503ee70cQ48783381-115b1e59-4bca-b340-7f91-b19e79642985Q49029823-64bbc93b-4b6b-c6a0-f662-f395399d1463Q49139597-be7ec082-4752-3266-68c1-68deb457564bQ49151586-6e03d595-4d5d-b71c-cb40-4ae7813ed563Q50639751-6f2fa3b5-40da-3b90-4cb5-3533ef47be61Q50665210-1ee1fdb8-4367-55e8-8693-d657fa69ae4cQ50673122-08c387f8-43ec-d2d2-1906-9900660f49fcQ51483067-be8e90d6-4c92-b730-ca5c-b4ebf92edab2Q53153248-de23381d-444b-bfe3-0ab5-37851133ce1dQ53579111-3e6b95cd-4c12-ed7a-862b-22e75d4decc2Q56905251-b4760b1a-4be6-b2e8-e994-fad71b39157aQ56912039-4a221b7f-4a99-8250-d88f-e7652f70c7fcQ67027705-96558a16-47e0-8bc2-4656-e8f45481542bQ67337701-da507bdc-4f24-54b0-3ab0-af98a633713aQ68673438-997a8ec2-4fac-c2e3-3f1d-a5500b8385dcQ70170514-756186be-4f26-6d9b-f8f2-ee2c8af9eda0Q70199737-751166a4-4473-90d8-9942-e602baffe832Q70406440-3fe8a92c-4ddd-5e50-c4b7-2eab185016aeQ70456346-720ae55a-40e1-2741-6dc7-7b7045f9baadQ70466239-0157209d-4c34-891a-35c4-45131743d3c1
P50
description
physician
@en
name
Geoffrey Sher
@en
type
label
Geoffrey Sher
@en
prefLabel
Geoffrey Sher
@en
P214
P227
P244
P106
P1153
7004582960
P21
P213
0000 0000 6732 3964
P214
P227
P244
P31
P569
1943-05-16T00:00:00Z
P6023
P734
P735
P7859
lccn-n83056335